RVB is classified as a pioneering menin inhibitor and is currently being developed to treat relapsed or refractory (R/R) KMT2A-rearranged acute leukemias, which include both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as NPM1-mutant AML. Here, NPM1 is linked to acute myeloid leukemia.